Objective To evaluate the safety and efficacy of sequential treatment with inetolimab,toripalimab combined with albumin paclitaxel in patients with HER-2 positive advanced breast cancer.Methods A case of HER2-positive stage ⅢA breast cancer was reported.The patient did not take anti-HER2 adjuvant treatment due to financial reasons after surgery.After the occurrence of multiple metastases,the patient entered the clinical trial,and received 8 cycles treatment of inetetamab,toripalimab and albumin paclitaxel.The sequential combination of inetetamab and toripalimab was sustained for 12 cycles.Results After 4 cycles of treatment,the patien was evaluated as complete response.The current progression-free survival has exceeded 16 months.The safety profile was good.Conclusion For HER2 positive advanced breast cancer,the combination of inetetamab,toripalimab and chemotherapy holds promise as a new first-line treatment option.
InetetamabToripalimabAlbumin paclitaxelAnti-HER2 therapyHER2-positive breast cancer
维普
万方数据
